Literature DB >> 21700891

Mesenteric lymph from rats with trauma-hemorrhagic shock causes abnormal cardiac myocyte function and induces myocardial contractile dysfunction.

Justin T Sambol1, Marlon A Lee, Mingshan Jiang, Garima Dosi, Wei Dong, Edwin A Deitch, Atsuko Yatani.   

Abstract

Myocardial contractile dysfunction develops following trauma-hemorrhagic shock (T/HS). We have previously shown that, in a rat fixed pressure model of T/HS (mean arterial pressure of 30-35 mmHg for 90 min), mesenteric lymph duct ligation before T/HS prevented T/HS-induced myocardial contractile depression. To determine whether T/HS lymph directly alters myocardial contractility, we examined the functional effects of physiologically relevant concentrations of mesenteric lymph collected from rats undergoing trauma-sham shock (T/SS) or T/HS on both isolated cardiac myocytes and Langendorff-perfused whole hearts. Acute application of T/HS lymph (0.1-2%), but not T/SS lymph, induced dual inotropic effects on myocytes with an immediate increase in the amplitude of cell shortening (1.4 ± 0.1-fold) followed by a complete block of contraction. Similarly, T/HS lymph caused dual, positive and negative effects on cellular Ca²⁺ transients. These effects were associated with changes in the electrophysiological properties of cardiac myocytes; T/HS lymph initially prolonged the action potential duration (action potential duration at 90% repolarization, 3.3 ± 0.4-fold), and this was followed by a decrease in the plateau potential and membrane depolarization. Furthermore, intravenous infusion of T/HS lymph, but not T/SS lymph, caused myocardial contractile dysfunction at 24 h after injection, which mimicked actual T/HS-induced changes; left ventricular developed pressure (LVDP) and the maximal rate of LVDP rise and fall (±dP/dt(max)) were decreased and inotropic response to Ca²⁺ was blunted. However, the contractile responsiveness to β-adrenergic receptor stimulation in the T/HS lymph-infused hearts remained unchanged. These results suggest that T/HS lymph directly causes negative inotropic effects on the myocardium and that T/HS lymph-induced changes in myocyte function are likely to contribute to the development of T/HS-induced myocardial dysfunction.

Entities:  

Mesh:

Year:  2011        PMID: 21700891      PMCID: PMC3174800          DOI: 10.1152/japplphysiol.00100.2011

Source DB:  PubMed          Journal:  J Appl Physiol (1985)        ISSN: 0161-7567


  38 in total

1.  Heart failure and the ryanodine receptor: does Occam's razor rule?

Authors:  D A Eisner; A W Trafford
Journal:  Circ Res       Date:  2002-11-29       Impact factor: 17.367

Review 2.  Nitric oxide and cardiac function: ten years after, and continuing.

Authors:  P B Massion; O Feron; C Dessy; J-L Balligand
Journal:  Circ Res       Date:  2003-09-05       Impact factor: 17.367

3.  Hemorrhage-induced alpha-adrenergic signaling results in myocardial TNF-alpha expression and contractile dysfunction.

Authors:  R Shahani; L V Klein; J G Marshall; S Nicholson; B B Rubin; P M Walker; T F Lindsay
Journal:  Am J Physiol Heart Circ Physiol       Date:  2001-07       Impact factor: 4.733

4.  Dissociation of myocardial contractility and pump performance in hemorrhagic shock. Correlation of in vivo measurements with assay of shock plasma in papillary muscle.

Authors:  J S Forrester; E A Amsterdam; W W Parmley; E H Sonnenblick; C W Urschel
Journal:  Cardiology       Date:  1972       Impact factor: 1.869

Review 5.  Altered beta-adrenergic receptor gene regulation and signaling in chronic heart failure.

Authors:  J D Port; M R Bristow
Journal:  J Mol Cell Cardiol       Date:  2001-05       Impact factor: 5.000

Review 6.  Integrative analysis of calcium signalling in cardiac muscle.

Authors:  Andrew W Trafford; M E Díaz; S C O'Neill; D A Eisner
Journal:  Front Biosci       Date:  2002-04-01

7.  A circulating myocardial depressant substance in humans with septic shock. Septic shock patients with a reduced ejection fraction have a circulating factor that depresses in vitro myocardial cell performance.

Authors:  J E Parrillo; C Burch; J H Shelhamer; M M Parker; C Natanson; W Schuette
Journal:  J Clin Invest       Date:  1985-10       Impact factor: 14.808

8.  Mesenteric lymph from rats with thermal injury prolongs the action potential and increases Ca2+ transient in rat ventricular myocytes.

Authors:  Atsuko Yatani; Da-Zhong Xu; Song-Jung Kim; Stephen F Vatner; Edwin A Deitch
Journal:  Shock       Date:  2003-11       Impact factor: 3.454

9.  A study of the biologic activity of trauma-hemorrhagic shock mesenteric lymph over time and the relative role of cytokines.

Authors:  Marson T Davidson; Edwin A Deitch; Qi Lu; Adena Osband; Eleonora Feketeova; Zoltán H Németh; Gyorgy Haskó; Da-Zhong Xu
Journal:  Surgery       Date:  2004-07       Impact factor: 3.982

10.  Myocyte nitric oxide synthase 2 contributes to blunted beta-adrenergic response in failing human hearts by decreasing Ca2+ transients.

Authors:  Mark T Ziolo; Lars S Maier; Valentino Piacentino; Julie Bossuyt; Steven R Houser; Donald M Bers
Journal:  Circulation       Date:  2004-03-22       Impact factor: 29.690

View more
  3 in total

1.  A "CLEAN CASE" OF SYSTEMIC INJURY: MESENTERIC LYMPH AFTER HEMORRHAGIC SHOCK ELICITS A STERILE INFLAMMATORY RESPONSE.

Authors:  Jeniann Yi; Anne Slaughter; Cassandra V Kotter; Ernest E Moore; Carl J Hauser; Kiyoshi Itagaki; Max Wohlauer; Daniel N Frank; Christopher Silliman; Anirban Banerjee; Erik Peltz
Journal:  Shock       Date:  2015-10       Impact factor: 3.454

Review 2.  Cardiovascular Effects of Shock and Trauma in Experimental Models. A Review.

Authors:  Mauricio Rocha-e-Silva
Journal:  Braz J Cardiovasc Surg       Date:  2016-02

3.  Mesenteric Lymph Duct Ligation Alleviates Acute Lung Injury Caused by Severe Acute Pancreatitis Through Inhibition of High Mobility Group Box 1-Induced Inflammation in Rats.

Authors:  Yishuang Tang; Jing Kong; Bingduo Zhou; Xiaosu Wang; Xiaowen Liu; Yi Wang; Shengliang Zhu
Journal:  Dig Dis Sci       Date:  2021-01-12       Impact factor: 3.199

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.